The Role of Adenosine Kinase in Controlling Beta-Cell Regeneration

腺苷激酶在控制 β 细胞再生中的作用

基本信息

  • 批准号:
    8888112
  • 负责人:
  • 金额:
    $ 39.67万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-09-01 至 2020-07-31
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): Recent decades have seen an incredible growth in the prevalence of diabetes. The increasing frequency of this disorder threatens the health of our society and puts into focus the current lack of adequate prevention and treatment options. While it is important to pursue multiple therapeutic strategies, harnessing the regenerative capacity of islet ß-cells to increase an individual's insulin secretion capacity is among the promising approaches. Recently, discovery-oriented unbiased chemical screening led to the identification of the metabolic enzyme adenosine kinase (ADK) as a regulator of rodent and porcine ß-cell replication. Importantly, small molecule ADK-inhibitors selectively stimulate replication of ß-cels, but not alpha-cells, in vitro and in vivo. The identification of ADK as a regulator of ß-cell regeneration has raised several important questions. Does long-term inhibition of ADK in vivo promote ß-cell mass expansion and protect against developing diabetes? How does a broadly expressed metabolic enzyme selectively control the growth of a specific cell- type? Importantly, mature human ß-cells are resistant to growth stimuli. Presently, there is very limited understanding of why human ß-cells appear to be replication incompetent. This proposal describes a systematic approach to answering these critical questions and to uncovering the molecular basis of human ß- cell growth resistance. Complementary experimental strategies of genetic and chemical inhibition of ADK are employed to assess the in vivo impact of disrupting ADK function and to understand how ADKis promote ß-cell replication. Additionally, the ability of ADK inhibitors to promote rodent ß-cell replication and innovative transcriptomic-based strategies are leveraged to uncover why human ß-cells are refractory to growth stimuli. The long-term aim of this work is to uncover methods of stimulating mature human ß-cell regeneration.
 描述(由申请人提供):近几十年来,糖尿病的患病率出现了令人难以置信的增长。这种疾病的日益频繁威胁着我们社会的健康,并使目前缺乏适当的预防和治疗选择成为焦点。虽然追求多种治疗策略是重要的,但利用胰岛β细胞的再生能力来增加个体的胰岛素分泌能力是有希望的方法之一。最近,以发现为导向的无偏化学筛选导致代谢酶腺苷激酶(ADK)被鉴定为啮齿动物和猪胰岛细胞复制的调节剂。重要的是,小分子ADK抑制剂在体外和体内选择性地刺激α-细胞而不是α-细胞的复制。ADK作为胰岛细胞再生调节因子的鉴定提出了几个重要的问题.体内长期抑制ADK是否促进胰岛细胞团的扩增并防止糖尿病的发生?广泛表达的代谢酶如何选择性地控制特定细胞类型的生长?重要的是,成熟的人β细胞对生长刺激具有抗性。目前,对于为什么人类β细胞似乎不能复制的理解非常有限。该提案描述了一个系统的方法来回答这些关键问题,并揭示人类乳腺癌细胞生长阻力的分子基础。采用ADK的遗传和化学抑制的补充实验策略来评估破坏ADK功能的体内影响,并了解ADK如何促进β细胞复制。此外,ADK抑制剂促进啮齿动物β-细胞复制的能力和基于转录组学的创新策略被用来揭示为什么人类β-细胞对生长刺激物不敏感。这项工作的长期目标是揭示刺激成熟人类胰岛细胞再生的方法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Justin Pierce Annes其他文献

Justin Pierce Annes的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Justin Pierce Annes', 18)}}的其他基金

Developing A Platform Technology For β-Cell-Targeted Drug Delivery
开发β细胞靶向药物输送的平台技术
  • 批准号:
    10729390
  • 财政年份:
    2023
  • 资助金额:
    $ 39.67万
  • 项目类别:
Development of Beta-Cell-Targeted Regenerative Therapeutics Using A Novel Prodrug Strategy
使用新型前药策略开发β细胞靶向再生疗法
  • 批准号:
    10215497
  • 财政年份:
    2019
  • 资助金额:
    $ 39.67万
  • 项目类别:
Development of Beta-Cell-Targeted Regenerative Therapeutics Using A Novel Prodrug Strategy
使用新型前药策略开发β细胞靶向再生疗法
  • 批准号:
    10661006
  • 财政年份:
    2019
  • 资助金额:
    $ 39.67万
  • 项目类别:
Development of Beta-Cell-Targeted Regenerative Therapeutics Using A Novel Prodrug Strategy
使用新型前药策略开发β细胞靶向再生疗法
  • 批准号:
    10453575
  • 财政年份:
    2019
  • 资助金额:
    $ 39.67万
  • 项目类别:
Enrichment Program
强化计划
  • 批准号:
    10197909
  • 财政年份:
    2017
  • 资助金额:
    $ 39.67万
  • 项目类别:
Leveraging the Uniquely High Beta-Cell Zinc Content for Targeted Drug Delivery
利用独特的高β细胞锌含量进行靶向药物输送
  • 批准号:
    10207073
  • 财政年份:
    2015
  • 资助金额:
    $ 39.67万
  • 项目类别:
Leveraging the Uniquely High Beta-Cell Zinc Content for Targeted Drug Delivery
利用独特的高β细胞锌含量进行靶向药物输送
  • 批准号:
    10576401
  • 财政年份:
    2015
  • 资助金额:
    $ 39.67万
  • 项目类别:
Leveraging the Uniquely High Beta-Cell Zinc Content for Targeted Drug Delivery
利用独特的高β细胞锌含量进行靶向药物输送
  • 批准号:
    10366072
  • 财政年份:
    2015
  • 资助金额:
    $ 39.67万
  • 项目类别:
Interrogating the Role of Adenosine Kinase in Islet Beta-Cells
探讨腺苷激酶在胰岛β细胞中的作用
  • 批准号:
    8480250
  • 财政年份:
    2013
  • 资助金额:
    $ 39.67万
  • 项目类别:
Interrogating the Role of Adenosine Kinase in Islet Beta-Cells
探讨腺苷激酶在胰岛β细胞中的作用
  • 批准号:
    8643226
  • 财政年份:
    2013
  • 资助金额:
    $ 39.67万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 39.67万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.67万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 39.67万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.67万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 39.67万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.67万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 39.67万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 39.67万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 39.67万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.67万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了